Polymedco

In honor of #ColorectalCancerAwarenessMonth, we wanted to share some important statistics. Colon cancer is the second deadliest cancer in the U.S.*, but it doesn’t have to be. By screening for colon cancer every year with OC-Auto FIT, average-risk adults ages 45-75 can catch cancer earlier and help keep themselves safe from this deadly disease. Learn more about the gold standard in non-invasive CRC screening at https://bit.ly/41kgY0G *Colorectal cancer statistics: How common is colorectal cancer? American Cancer Society.

Upcoming webinar alert, with over 700 people already registered! Join Polymedco and ADLM on Thursday, March 27th at 1 PM EST to learn more about the clinical use of high-sensitivity cardiac troponin (hs-cTn) in POC settings for the diagnosis of myocardial infarction (MI). Learn how hs-cTn assays differ in the US compared to Europe, Australia, and Canada, understand the impact of FDA regulations on clinical algorithms, and explore the latest evidence on point-of-care hs-cTn assays in the webinar led by Dr Luca Koechlin, MD. Register now to secure your spot! https://bit.ly/4iGn2Z4

Early screening saved a life. This #ColorectalCancerAwarenessMonth watch Gladys’ heartwarming story from the Rewriting Cancer series, where she shares her CRC screening experience. Learn how OC-Auto FIT test saved a patient’s life: https://bit.ly/41zKelD BBC StoryWorks

Upcoming webinar alert! Join Polymedco and ADLM on Thursday, March 27th at 1 PM EST to learn more about the clinical use of high-sensitivity cardiac troponin (hs-cTn) in POC settings for the diagnosis of myocardial infarction (MI). Learn how hs-cTn assays differ in the US compared to Europe, Australia, and Canada, understand the impact of FDA regulations on clinical algorithms, and explore the latest evidence on point-of-care hs-cTn assays in the webinar led by Dr Luca Koechlin, MD. Register now to secure your spot! https://bit.ly/43lwn3v

As part of #ColorectalCancerAwarenessMonth, visit Polymedco’s patient website, filled with resources about colon cancer, the importance of annual screening, and how OC-Auto? FIT makes at-home screening easy. If you are 45-75 and at average risk for colon cancer, or know someone who is, visit the site at https://bit.ly/3CX83KH to get your screening test today.

It’s Colorectal Cancer (CRC) Awareness Month. Are you up to date on the latest, new insights from JAMA on CRC screening?* ?Did you know that annual FIT is shown to be the most clinically and cost-effective non-invasive CRC screening method? ?Did you know that annual FIT outperforms triennial mt-sDNA and triennial blood testing—not just in perfect conditions, but in real-world scenarios too? ?Did you know that annual FIT results in more life-years gained, lower costs, and the greatest net monetary benefit compared to other non-invasive options? Screening decisions matter. Learn more about the importance of ANNUAL CRC screening with OC-Auto FIT: https://bit.ly/4bkLNqz *Nascimento de Lima JAMA Network Open. 2025 ** 100% adherence to screening, follow-up colonoscopy, and surveillance colonoscopy *** 45% adherence for FIT or mt-sDNA screening and 62.5% adherence for blood-based testing with 40% adherence to follow-up colonoscopy

Upcoming webinar alert! Join Polymedco and ADLM on Thursday, March 27th at 1 PM EST to learn more about the clinical use of high-sensitivity cardiac troponin (hs-cTn) in POC settings for the diagnosis of myocardial infarction (MI). Learn how hs-cTn assays differ in the US compared to Europe, Australia, and Canada, understand the impact of FDA regulations on clinical algorithms, and explore the latest evidence on point-of-care hs-cTn assays in the webinar led by Dr Luca Koechlin, MD. Register now to secure your spot! https://bit.ly/41G2VEg

Colorectal cancer (CRC) is the second-deadliest type of cancer in the United States, with over 50 thousand annual deaths estimated.* However, 9 out of 10 CRC deaths can be prevented when caught early.** This #ColorectalCancerAwarenessMonth, we at Polymedco are eager to raise awareness about annual CRC screening with OC-Auto FIT and how it promotes early detection. Learn more about the importance of annual screening at https://bit.ly/4h1odQS *https://bit.ly/3D5TkwY **Tepus. Gastrointest Tumors. 2020

New research supports FIT as the most clinically and cost-effective noninvasive colorectal cancer screening method.* A recent study published in JAMA Network Open compared annual FIT with other noninvasive screening methods, including multi-target stool DNA (mt-sDNA) and blood-based tests. The findings? Annual FIT was the most effective screening strategy in terms of life years gained and cost efficiency in both perfect and realistic adherence scenarios. This independent data reinforces that annual OC-Auto FIT provides the best balance of accuracy, accessibility, and affordability.  Read the press release to learn more here: https://prn.to/4hMeDCK *Nascimento de Lima. JAMA Netw Open. 2025.

Screening for average-risk people starts at age 45, but did you know you have many options when it comes to colorectal cancer screening? A gastroenterologist can do a colonoscopy to find and remove polyps before they become cancer, while non-invasive screenings like a Fecal Immunochemical Test (FIT) and other stool-based testing require no sedation and do not require bowel prep. It’s important to remember that if a non-invasive screening returns abnormal results, a colonoscopy is required to complete your screening. Talk to your healthcare provider about which option is right for you, and read more about your screening options?? https://ow.ly/bq2K50UM2po